Abstract
In this project, carried out in partnership with the Institute of Technology in Immunobiologicals of the Oswaldo Cruz Foundation (Bio-Manguinhos), a Glycoengineering strategy will be explored to produce a biosimilar recombinant monoclonal antibody anti-PD-1 aiming to expand access to the Nivolumab antibody (OPDIVO, Bristol Myers Squibb). The objective is to introduce the alpha-2,6 sialyla…